Einstein/Montefiore Department of Medicine

Department Faculty

Dr. Amit K. Verma, M.B.B.S.

Amit K. Verma, M.B.B.S.

Professor, Department of Medicine (Oncology)

Professor, Department of Developmental & Molecular Biology

Director, Division of Hemato-Oncology, Montefiore Department of Oncology

Areas of Research: Myelodysplastic syndrome (MDS) are hematologic malignancies characterized by ineffective hematopoiesis. We study the molecular pathogenesis of MDS to identify targetable pathways for treatment of this disease.

Professional Interests


Targeting signal transduction in hematologic malignancies
Cytokines play important roles in the regulation of normal hematopoiesis and a balance between the actions of hematopoietic growth factors and myelosuppressive factors is required for optimal production of different hematopoietic cell lineages. The myelodysplastic syndromes (MDS) are collections of heterogeneous hematologic diseases characterized by refractory cytopenias due to ineffective hematopoiesis. These preleukemic disorders are common causes of anemia in the elderly and are rapidly increasing in incidence. We have also demonstrated that the TGF-beta superfamily/smad, IRAK and MAP kinase pathways is overactivated in MDS. Our work has led to clinical trials with Luspatercept, Galunisertib, CA4948, ARRY-614 and various other promising agents in MDS. We are trying to study the molecular mechanisms that lead to the activation of these pathways in MDS and are using small molecule inhibitors in mouse models to target these pathways. 

Targeting aberrant stem and progenitor cells in myelodysplastic neoplasms: 
We have demonstrated that aberrant stem cells persist during morphological remissions and are involved in relapse. We have identified novel targets against MDS/AML stem cells that are being tested in various studies. We are also conducting sequencing/epigenetic analysis of highly purified human stem cells and evaluating the role of these alterations in transformation of MDS to AML. 

Epigenomic analysis of tumors:
We are using high throughput assays to analyze DNA methylation across the genome and have optimized these assays to work with low amounts of DNA. We have successfully used these assays in conducting an integrative analysis of epigenetic and genetic alterations in various tumor models, including MDS, esophageal cancer, pancreatic cancer and renal cell cancer.

Clinical studies in Myelodysplastic syndromes:
We have a “center of excellence” clinic for patients with Myelodysplatic syndromes. We offer a variety of clinical trials for these patients (www.mdstreatment.com).

Selected Publications

  1. Su H, Jiang M, Senevirathne C, Aluri S, Zhang T, Guo H, Xavier-Ferrucio J, Jin S, Tran NT, Liu SM, Sun CW, Zhu Y, Zhao Q, Chen Y, Cable L, Shen Y, Liu J, Qu CK, Han X, Klug CA, Bhatia R, Chen Y, Nimer SD, Zheng YG, Iancu-Rubin C, Jin J, Deng H, Krause DS, Xiang J, Verma A*, Luo M*, Zhao X*. Methylation of dual-specificity phosphatase 4 controls cell differentiation. Cell Rep. 2021 Jul 27;36(4):109421. PMID: 34320342. *Co-Corresponding.
  2. Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, Rahman S, Kim SY, Ko B, Sica RA, Kornblum N, Bachier-Rodriguez L, McCort M, Goel S, Perez-Soler R, Packer S, Sparano J, Gartrell B, Makower D, Goldstein YD, Wolgast L, Verma A*, Halmos B*. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell. 2021 Jun 5: PMID: 34133951; PMCID: PMC8179248. *Co-Corresponding
  3. Ueda K, Kumari R, Schwenger E, Wheat JC, Bohorquez O, Narayanagari SR, Taylor SJ, Carvajal LA, Pradhan K, Bartholdy B, Todorova TI, Goto H, Sun D, Chen J, Shan J, Song Y, Montagna C, Pellagatti A, Boultwood J, Xiong S, Lozano G, Verma A, Steidl U. MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism. Cancer Cell. 2021 Apr 12;39(4):529-547.e7. PMID: 33667384.
  4. Weinreb JT, Ghazale N, Pradhan K, Gupta V, Potts KS, Tricomi B, Daniels NJ, Padgett RA, Oliveira SD, Verma A, Bowman TV Excessive R-loops Trigger an Inflammatory Cascade Leading to Increased HSPC Production Dev Cell, 2021, Mar 8;56(5):627-640. PMID: 33651979.
  5. Shapiro LC, Mustafa J, Lombardo A, Khatun F, Joseph F, Gillick K, Naik A, Elkind R, Abreu M, Fehn K, de Castro A, Pradhan K, Binakaj D, Nelson R, Paroder M, Uehlinger J, Gritsman K, Alejandro Sica R, Kornblum N, Shastri A, Mantzaris I, Bachier-Rodriguez L, Verma A, Braunschweig I, Goldfinger M. Safety of axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma in an elderly intercity population. Bone Marrow Transplant. 2021 Jul;56(7):1761-1763. PMID: 33846558.
  6. Thakkar A, Pradhan K, Jindal S, Cui Z, Rockwell B, Shah AP, Packer S, Sica RA, Sparano J, Goldstein DY, Verma A, Goel S, Halmos B Patterns of seroconversion for SARS-CoV2-IgG in patients with malignant disease and association with anti-cancer therapy Nature Cancer, 2021, 2: 392–399.
  7. Mehta V*, Goel S*, Kabarriti R*, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B*, Verma A*. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer Discov. 2020 Jul;10(7):935-941. PMID: 32357994; PMCID: PMC7334098.
  8. List AF, Sun Z, Verma A*, Bennett JM, Komrokji RS, McGraw K, Maciejewski J, Altman J, Cheema PS, Claxton DF, Luger SM, Mattison RJ, Wassenaar T, Artz AA, Schiffer CA, Litzow MR, Tallman MS Lenalidomide-Epoetin Alfa versus Lenalidomide-monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin JCO, 2021, Jan 13: PMID: 33439748 *Corresponding.
  9. COVID-19 and Cancer Consortium. A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. Cancer Cell. 2020 Dec 14;38(6):761-766. PMID: 33176160; PMCID: PMC7598547.
  10. Kuderer NM, Choueiri TK, et al. Mishra S, Lyman GH, Rini BI, Warner JL; COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020 Jun 20;395(10241):1907-1918. PMID: 32473681; PMCID: PMC7255743.
  11. Verma A, Suragani RN, Aluri S, Shah N, Bhagat TD, Alexander MJ, Komrokji R, Kumar R. Biological basis for efficacy of activing receptor ligand traps in myelodysplastic syndromes. J Clin Invest. 2020 Feb 3;130(2):582-589. doi: 10.1172/JCI133678. Review. PMID: 31961337
  12. Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Díez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Giai V, Vyas P, Bowen D, Selleslag D, DeZern AE, Jurcic JG, Germing U, Götze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellström-Lindberg E, Zeidan AM, Adès L, Verma A, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. N Engl J Med. 2020 Jan 9;382(2):140-151. PMID: 31914241
  13. Bhagat TD, Ahrens DV, Dawlaty M, Zou Y, Baddour J, Achreja A, Zhao H, Yang L, Patel N, Kwak C,  Choudhary G, Gordon-Mitchell S, Alluri S, Bhattacharyya S, Yu Y, Bartenstein M, Giricz O, Suzuki M, Sohal D, Gupta S, Batra S, Goggins M, Steidl U, Greally J, Agarwal B, Pradhan K, Banerjee D, Nagrath D*, Maitra A*,  Verma A*. Lactate-mediated Epigenetic Reprogramming Regulates Formation of Pancreatic Cancer-associated Fibroblasts Elife, Oct 30;8, 2019, (In Press)* Equal Contribution PMID: 31663852
  14. Santini V, Valcárcel D, Platzbecker U, Komrokji RS, Cleverly AL, Lahn MM, Janssen J, Zhao Y, Chiang A, Giagounidis A, Guba SC, Gueorguieva I, Girvan AC, da Silva Ferreira M, Bhagat TD, Pradhan K, Steidl U, Sridharan A, Will B, Verma A. Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes. Clin Cancer Res. 2019 Sep 3. PMID: 31481511
  15. Smith M*, Choudhary GS*, Pellagatti A, Choi K, Bhagat TD, Gordon-Mitchell S, Von Ahrens D, Pradhan K, Steeples V , Kim S, Steidl U , Salomonis N , Walter M, Komurov K, Boultwood J*, Verma A*, Starczynowski D*
    U2AF1 mutations induce oncogenic innate immune pathways by regulating the expression of active IRAK4 isoforms in hematologic malignancies. Nature Cell Bio 2019 May;21(5):640-650 * Equal Contribution 
  16. Jeong JJ, Gu X, Nie J, Sundaravel S, Liu H, Kuo W, Bhagat TD, Pradhan K, Cao J, Nischal S, McGraw K, Bhattacharyya S, Bishop M, Artz A, Thirman M, Moliterno AR, Ji P, Levine RL, Godley LA, Steidl U, Beiker J, List AF, Saunthararajah Y, He C, Verma A,* Wickrema A*
    Cytokine regulated phosphorylation and activation of TET2 by JAK2 in hematopoiesis Cancer Discovery 2019 Jun;9(6):778-795 * Equal Contribution
  17. Bhagat TD, Ahrens DV, Dawlaty M, Zou Y, Baddour J, Achreja A, Zhao H, Yang L, Patel N, Kwak C,  Choudhary G, Gordon-Mitchell S, Alluri S, Bhattacharyya S, Yu Y, Bartenstein M, Giricz O, Suzuki M, Sohal D, Gupta S, Batra S, Goggins M, Steidl U, Greally J, Agarwal B, Pradhan K, Banerjee D, Nagrath D*, Maitra A*,  Verma A*. Lactate-mediated Epigenetic Reprogramming Regulates Formation of Pancreatic Cancer-associated Fibroblasts Elife, Oct 30;8, 2019, (In Press)* Equal Contribution PMID: 31663852
  18. Santini V, Valcárcel D, Platzbecker U, Komrokji RS, Cleverly AL, Lahn MM, Janssen J, Zhao Y, Chiang A, Giagounidis A, Guba SC, Gueorguieva I, Girvan AC, da Silva Ferreira M, Bhagat TD, Pradhan K, Steidl U, Sridharan A, Will B, Verma A. Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes. Clin Cancer Res. 2019 Sep 3. PMID: 31481511
  19. Smith M*, Choudhary GS*, Pellagatti A, Choi K, Bhagat TD, Gordon-Mitchell S, Von Ahrens D, Pradhan K, Steeples V , Kim S, Steidl U , Salomonis N , Walter M, Komurov K, Boultwood J*, Verma A*, Starczynowski D*
    U2AF1 mutations induce oncogenic innate immune pathways by regulating the expression of active IRAK4 isoforms in hematologic malignancies. Nature Cell Bio 2019 May;21(5):640-650 * Equal Contribution 
  20. Jeong JJ, Gu X, Nie J, Sundaravel S, Liu H, Kuo W, Bhagat TD, Pradhan K, Cao J, Nischal S, McGraw K, Bhattacharyya S, Bishop M, Artz A, Thirman M, Moliterno AR, Ji P, Levine RL, Godley LA, Steidl U, Beiker J, List AF, Saunthararajah Y, He C, Verma A,* Wickrema A*
    Cytokine regulated phosphorylation and activation of TET2 by JAK2 in hematopoiesis
    Cancer Discovery 2019 Jun;9(6):778-795 * Equal Contribution
  21. Chen J, Kao Y, Sun D, Todorova T, Reynolds D, Narayanagari SR, Montagna C, Will B, Verma A*, Steidl U*Myelodysplastic Syndrome Progression to Acute Myeloid Leukemia at the Stem Cell Level Nature Medicine 2018, Jan;25(1):103-110 * Equal Contribution
  22. Shastri A, Choudhary G, Teixeira M, Gordon-Mitchell S, Ramachandra N, Bernard L, Bhattacharyya, S. Lopez, R. Pradhan, K. Giricz, O. Ravipati, G. Wong, L. F. Cole, S. Bhagat, T. D. Feld, J. Dhar, Y. Bartenstein, M. Thiruthuvanathan, V. J.  Wickrema, A. Ye, B. H. Frank, D. A. Pellagatti, A. Boultwood, J. Zhou, T. Kim, Y. MacLeod, A. R. Epling-Burnette, P. K. Ye, M. McCoon, P. Woessner, R. Steidl, U. Will, B. Verma, A. Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells. J Clin Invest. 2018 Sep 25. PMID: 30252677
  23. Shah UA, Chung EY, Giricz O, Pradhan K, Kataoka K, Gordon-Mitchell S, Bhagat TD, Mai Y, Wei Y, Ishida E, Choudhary GS, Joseph A, Rice R, Gitego N, Parrish C, Bartenstein M, Goel S, Mantzaris I, Shastri A, Derman O, Binder A, Gritsman K, Kornblum N, Braunschweig I, Bhagat C, Hall J, Graber A, Ratner L, Wang Y, Ogawa S, Verma A*, Ye BH*, Janakiram M.* North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies. Blood. 2018 Aug 13. PMID: 30104217 * Equal Contribution
  24. Landgren O*, Zeig-Owens R*, Giricz O*, Goldfarb D, Murata K, Thoren K, Ramanathan L, Hultcrantz M, Dogan A, Nwankwo G, Steidl S, Pradhan K, Hall C, Cohen HW, Jaber N, Schwartz T, Crowley L, Crane M, Irby S, Webber MP, Verma A*, Prezant DJ* Multiple Myeloma and Its Precursor Disease among Firefighters Exposed to the World Trade Center Disaster JAMA Onc, 2018 Jun 1;4(6):821-827. PMID: 29710195  * Equal Contribution
  25. Kao YR, Chen J, Narayanagari SR, Todorova TI, Aivalioti MM, Ferreira M, Ramos PM, Pallaud C, Mantzaris I, Shastri A, Bussel JB, Verma A, Steidl U, Will B. Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag. Sci Transl Med. 2018 Sep 12;10(458). PMID: 30209246
  26. Giricz O, Mo Y, Dahlman KB, Cotto-Rios XM, Vardabasso C, Nguyen H, Matusow B, Bartenstein M, Polishchuk V, Johnson DB, Bhagat TD, Shellooe R, Burton E, Tsai J, Zhang C, Habets G, Greally JM, Yu Y, Kenny PA, Fields GB, Pradhan K, Stanley ER, Bernstein E, Bollag G, Gavathiotis E, West BL, Sosman JA, Verma AK The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma. JCI Insight. 2018 Jul 25;3(14). PMID: 30046005
  27. Carvajal LA, Ben-Neriah D, Senecal A, Benard L, Thiruthuvanathan V, Yatsenko T, Narayanagari SR, Wheat JC, Todorova TI, Mitchell KM, Kenworthy C, Guerlavais V, Annis DA, Bartholdy B, Will B, Anampa JD, Mantzaris I, Aivado M, Singer RH, Coleman RA, Verma A, Steidl U. Dual inhibition of MDMX and MDM2 as a Therapeutic Strategy in Leukemia. Sci Transl Med. 2018, Apr 11;10(436). PMID: 29643228
  28. Mitchell K, Barreyro L, Todorova TI, Taylor SJ, Antony-Debré I, Narayanagari SR, Carvajal LA, Leite J, Piperdi Z, Pendurti G, Mantzaris I, Paietta E, Verma A, Gritsman K, Steidl U.  IL1RAP potentiates multiple oncogenic signaling pathways in AML. J Exp Med. 2018 Jun 4;215(6):1709-1727 PMID: 29773641
  29. Bhattacharyya S, Pradhan K, Campbell N, Mazdo J, Vasantkumar A, Maqbool S, Bhagat TD, Gupta S, Suzuki M, Yu Y, Greally JM, Steidl U, Bradner J, Dawlaty M, Godley L, Maitra A, Verma A, “Altered hydroxymethylation is seen at regulatory regions in pancreatic cancer and regulates oncogenic pathways,”  Genome Res, 2017, Oct 6. PMID: 28986391
  30. Bhagat TD, Chen S, Bartenstein M, Barlowe AT, Von Ahrens D, Choudhary GS, Tivnan P, Amin E, Marcondes M, Sanders MA, Hoogenboezem RM, Kambhampati S, Ramachandra N, Mantzaris I, Sukrithan V, Laurence R, Lopez R, Bhagat P, Giricz O, Sohal D, Wickrema A, Yeung C, Gritsman K, Aplan P, Hochedlinger K, Yu Y, Pradhan K, Zhang J, Greally JM,  Mukherjee SM, Pellagatti A, Boultwood J, Will B, Steidl U, Raaijmakers MHGP, Deeg HJ, Kharas MG, Verma A, “Wnt/ß-catenin activation by epigenetically aberrant stroma drives myelodysplastic syndrome,” Cancer Research Jul, 2017, PMID: 28684528
  31. Reyna DE, Garner TP, Lopez A, Kopp F, Choudhary GS, Sridharan A, Narayanagari SR, Mitchell K, Dong B, Bartholdy BA, Walensky LD, Verma A, Steidl U, Gavathiotis E. Direct “Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia,”  Cancer Cell 2017 Oct 9.PMID: 29017059 
  32. Antony-Debré I, Paul A, Leite J, Mitchell K, Kim HM, Carvajal LA, Todorova TI, Huang K, Kumar A, Farahat AA, Bartholdy B, Narayanagari SR, Chen J, Ambesi-Impiombato A, Ferrando AA, Mantzaris I, Gavathiotis E, Verma A, Will B, Boykin DW, Wilson WD, Poon GM, Steidl U., “Pharmacological inhibition of the transcription factor PU.1 in leukemia,”  J Clin Invest 2017 Oct 30, PMID: 29083320
  33. Yue L, Bartenstein M, Zhao W, Ho W, Murdun C, Mailloux AW, Zhang L, Budhakoti A, Pradhan K, Rapaport F, Wang H, Shao Z, Steidl U, Levine RL, Zhao ZJ, Verma A*, Epling-Burnette PK* (*Co-Corresponding), “Efficacy of ALK5 Inhibition in Myelofibrosis.”   JCI Insight (In Press)
  34. Bhagat TD, Zou Y, Huang S, Park J, Palmer MB, Hu C, Li W, Shenoy N, Giricz O, Choudhary G, Yu Y, Ko YA, Izquierdo MC, Park ASD, Vallumsetla N, Laurence R, Lopez R, Suzuki M, Pullman J, Kaner J, Gartrell B, Hakimi AA, Greally JM, Patel B, Benhadji K, Pradhan K, Verma A*, Susztak K* (*Co-Corresponding), “Notch pathway is activated via genetic and epigenetic alterations and is a therapeutic target in clear cell renal cancer .”  JBC 2016, Dec 1. PMID: 2790905
  35. Bachegowda L, Morrone K, Winski SL, Mantzaris I, Bartenstein M, Ramachandra N, Giricz O, Sukrithan V, Nwankwo G, Shahnaz S , Bhagat T, Bhattacharyya S, Assal A, Shastri A,  Gordon-Mitchell S, Pellagatti A, Boultwood J, Schinke C, Yu Y, Guha C, Rizzi J, Garrus J, Brown S, Wollenberg L, Hogeland G, Wright D, Munson M`, Rodriguez M, Gross S, Chantry D, Zou Y, Platanias L, Burgess LE, Pradhan K, Steidl U, Verma A,  “Pexmetinib: a novel dual inhibitor of Tie-2 and p38 MAPK with efficacy in preclinical models of myelodysplastic syndromes and acute myeloid leukemia.”  Cancer Res 2016 Jun 10. PMID: 27287719
  36. Goel S, Hall J, Pradhan K, Hirsch C, Przychodzen B, Shastri A, Mantzaris I,  Janakiram M, Battini R, Kornblum N, Derman O, Gritsman K, Al-Hafidh J, Wang Y, Halmos B, Steidl U, Maciejewski J, Braunschweig I, Verma A, “High Prevalence and Allele Burden Independent Prognostic Importance of p53 Mutations in an Inner-City MDS/AML Cohort,”  Leukemia 2016 Apr 29. PMID: 27125205
  37. Taggart J, Ho TC, Amin E, Xu H, Barlowe TS, Perez AR, Durham BH, Tivnan P, Okabe R, Chow A, Vu L, Park SM, Prieto C, Famulare C, Patel M, Lengner CJ, Verma A, Roboz G, Guzman M, Klimek VM, Abdel-Wahab O, Leslie C, Nimer SD, Kharas MG. “MSI2 is required for maintaining activated myelodysplastic syndrome stem cells.”  Nat Commun. 2016 Feb 22;7:10739. PMID: 26898884
  38. Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, Götze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A., “Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.”  Lancet Haematol. 2015 Oct;2(10):e417-26. PMID: 26686043
  39. Sundaravel S, Duggan R, Bhagat TD, Ebenezer D, Liu H, Yu Y, Bartenstein M, Unnikrishnan M, Karmakar S, Liu TC, Anastasi J, McGraw K, Pellagatti A, Boultwood J, Yajnik V, Artz A, Le Beau M, Steidl U, List A, Evans T*, Verma A*, Wickrema A*. (*Co-Corresponding),  “Reduced DOCK4 Expression Leads to Erythroid Dysplasia in Myelodysplastic Syndromes.”  PNAS 2015; Nov 17;112(46): PMID: 26578796
  40. Okoye-Okafor UC, Bartholdy B, Cartier J, Gao EN, Pietrak B, Rendina AR, Rominger C, Quinn C, Smallwood A, Wiggall KJ, Reif AJ, Schmidt SJ, Qi H, Zhao H, Joberty G, Faelth-Savitski M, Bantscheff M, Drewes G, Duraiswami C, Brady P, Groy A, Narayanagari SR, Antony-Debre I, Mitchell K, Wang HR, Kao YR, Christopeit M, Carvajal L, Barreyro L, Paietta E, Makishima H, Will B, Concha N, Adams ND, Schwartz B, McCabe MT, Maciejewski J, Verma A, Steidl U., “New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.’ Nature Chem Biol. 2015 Oct 5. PMID: 26436839
  41. PAK1 Pandolfi A, Stanley RF, Yu Y, Bartholdy B, Pendurti G, Gritsman K, Boultwood J, Chernoff J, Verma A, Steidl U, “PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.” Blood. 2015 Jul 13. PMID: 26170031
  42. Cabrero M, Yu Y, Verma A, Yang H, Colla S, Jia Y, Zheng H, Bohannan Z, Ganan-Gomez I, Futreal A, Takahashi K, Chin L, Kantarjian H, Pellagatti A, Bowman T, Boultwood J, Garcia-Manero G, Wei Y, “Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion.” Br J Haematol. 2015 Jun 24. PMID: 26105212
  43. Vardabasso C, Gaspar-Maia A, Hasson D, Pünzeler S, Valle-Garcia D, Straub T, Keilhauer EC, Strub T, Dong J, Panda T, Chung CY, Yao JL, Singh R, Segura MF, Fontanals-Cirera B, Verma A, Mann M, Hernando E, Hake SB, Bernstein E, “Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma.” Mol Cell. 2015 Jun 3. PMID: 26051178
  44. Sassano A, Mavrommatis E, Arslan AD, Kroczynska B, Beauchamp EM, Khuon S, Chew TL, Green KJ, Munshi HG, Verma AK, Platanias LC, “Human Schlafen 5 (SLFN5) is a Regulator of Motility and Invasiveness of Renal Cell Carcinoma  Cells.” Mol Cell Biol. 2015 May 26. PMID: 26012550
  45. Saleiro D, Mehrotra S, Kroczynska B, Beauchamp EM, Lisowski P, Majchrzak-Kita B, Bhagat TD, Stein BL, McMahon B, Altman JK, Kosciuczuk EM, Baker DP, Jie C, Jafari N, Thompson CB, Levine RL, Fish EN, Verma A, Platanias LC, “Central Role of ULK1 in Type I Interferon Signaling.” Cell Reports 2015, Apr 28;11(4):605-17. PMID: 25892232
  46. Cimmino L, Dawlaty MM, Ndiaye-Lobry D, Yap YS, Bakogianni S, Yu Y, Bhattacharyya S, Shaknovich R, Geng H, Lobry C, Mullenders J, King B, Trimarchi T, Aranda-Orgilles B, Liu C, Shen S, Verma A, Jaenisch R, Aifantis I, “TET1 is a tumor suppressor of hematopoietic malignancy.” Nat Immunol. 2015 Apr 13. PMID: 25867473
  47. Schinke C, Giricz O, Li W, Shastri A, Gordon S, Barreryo L, Bhagat T, Bhattacharyya S, Ramachandra N, Bartenstein M, Pellagatti A, Boultwood J, Wickrema A, Yu Y, Will W, Wei S, Steidl U*, Verma A*,   *co-corresponding authors, “IL8-CXCR2 pathway inhibition as a novel therapeutic strategy against MDS and AML stem cells.” Blood. 2015, Mar 25. PMID: 25810490               
  48. Gerstung M, Pellagatti A, Malcovati L, Giagounidis A, Porta MG, Jädersten M, Dolatshad H, Verma A, Cross NC, Vyas P, Killick S, Hellström-Lindberg E, Cazzola M, Papaemmanuil E, Campbell PJ, Boultwood J, “Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic Syndromes.” Nat Commun. 2015 Jan 9;6:5901. PMID: 25574665 
  49. Caescu CI, Guo X, Tesfa L, Bhagat TD, Verma A, Zheng D, Stanley ER, “Colony stimulating factor-1 receptor signaling networks inhibit mouse macrophage inflammatory responses by induction of microRNA-21.” Blood. 2015 Jan 8. PMID: 25573988
  50. Will B, Vogler TO, Narayanagari S, Bartholdy B, Todorova TI, Ferreira M, Chen J, Yu Y, Mayer J, Barreyro L, Carvajal L, Ben Neriah D, Roth M, van Oers J, Schaetzlein S, McMahon C, Edelmann W, Verma A, Steidl U, “Minimal reduction of PU.1 is sufficient to induce a preleukemic state and promote development of acute myeloid leukemia.” Nature Medicine, 2015 (In Print)
  51. Shrivastava MS, Hussain Z, Giricz O, Shenoy N, Polineni R, Maitra A, Verma A, “Targeting chemokine pathways in esophageal adenocarcinoma.” Cell Cycle. 2014 Nov 1;13(21):3320-7. PMID: 25485576
  52. Sridharan A, Jain R, Bachhuber MA, Yu Y, Ramesh Kh, Gundabolu K, Friedman EW, Verma AK, “Epidemiologic study of myelodysplastic syndromes in a multiethnic, inner city cohort.” Exp Hematol Oncol. 2014 Aug 23;3:22. PMID: 25170429
  53. Hu C, Mohtat D, Yu Y, Ko YA, Shenoy N, Bhattacharyya S, Izquierdo MC, Park AS, Giricz O, Vallumsetla N, Gundabolu K, Ware K, Bhagat T, Suzuki M, Pullman J, Liu SX, Greally J, Susztak K, Verma A, “Kidney cancer is characterized by aberrant methylation of tissue specific enhancers that are prognostic for overall survival.” Clin Cancer Res. 2014 Jun 10. PMID: 24916699
  54. Mariani CJ, Vasanthakumar A, Madzo J, Yesilkanal A, Bhagat T, Yu Y, Bhattacharyya S, Wenger R, Cohn S, Nanduri J, Verma A, Prabhakar N, Godley LA, “TET1-Mediated Hydroxymethylation Facilitates Hypoxic Gene Induction in Neuroblastoma.” Cell Rep. 2014 May 14. PMID: 24835990
  55. Keerthivasan G, Mei Y, Zhao B, Zhang L, Harris CE, Gao J, Basiorka AA, Schipma MJ, McElherne J, Yang J, Verma AK, Pellagatti A, Boultwood J, List AF, Williams DA, Ji P., “Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) myelodysplastic syndromes.” Blood. 2014 Jun 2. PMID: 24891322
  56. Tamari R,  Schinke C, Bhagat T, Roth M, Braunschweig I,  Will B,  Steidl U, Verma A, “Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone.” Leuk Lymphoma, 2014 Dec;55(12):2901-6.PMID: 24650011
  57. Bartholdy B, Christopeit M, Will B, Mo Y, Barreyro L, Yu Y, Bhagat T, Okoye-Okafor U, Todorova T, Greally J, Levine RL, Melnick A, Verma A*, Steidl U, *Co-Corresponding, “A human hematopoietic stem cell-commitment related DNA cytosine methylation signature is prognostic for overall survival in acute myeloid leukemia.” Journal of Clinical Investigation 2014 Feb 3 PMID: 24487588
  58. Msaouel P, Lam AP, Gundabolu K, Chrysofakis G, Yu Y, Mantzaris I, Friedman E, Verma A, “Abnormal platelet count is an independent predictor of mortality in the elderly and is influenced by ethnicity.” Haematologica, 2014 Feb 7. PMID: 24510340
  59. Kuo P, Leshchenko V, Fazzari M, Gellen T, Iqbal J, Baumgartner-Wennerholm S, Nygren L, Zhang F, Zhang W, Suh K, Goy A, Yang D, Chan W, Kahl B, Verma A, Gascoyne R, Kimby E, Sander B, Ye BH, Melnick A, Perumal D, He T, Parekh S, “High resolution Chromatin Immunoprecipitation (ChIP) sequencing reveals novel bindings targets and prognostic role for SOX11 in Mantle cell lymphoma.”      Oncogene, 2014 Mar 31 PMID: 24681958
  60. Hosono N, Makishima H, Jerez A, Yoshida K, Przychodzen B, McMahon S, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Sanada M, Gómez-Seguí I, Verma AK, McDevitt MA, Sekeres MA, Ogawa S, Maciejewski JP, “Recurrent genetic defects on chromosome 7q in myeloid neoplasms.”Leukemia 2014 Jan 16. PMID: 24429498
  61. Madzo J, Liu H, Rodriguez A, Vasanthakumar A, Sundaravel S, Caces DB, Looney TJ, Zhang L, Lepore JB, Macrae T, Duszynski R, Shih AH, Song CX, Yu M, Yu Y, Grossman R, Raumann B, Verma A, He C, Levine RL, Lavelle D, Lahn BT, Wickrema A, Godley LA, “Hydroxymethylation at Gene Regulatory Regions Directs Stem/Early Progenitor Cell Commitment during Erythropoiesis.” Cell Reports 2013 Dec 24 PMID: 24373966
  62. Ko YA, Mohtat D, Suzuki M, Park AS, Izquierdo MC, Han SY, Kang HM, Si H, Hostetter T, Pullman JM, Fazzari M, Verma A, Zheng D, Greally JM, Susztak K, “Cytosine methylation changes in enhancer regions of core pro-fibrotic genes characterize kidney fibrosis development.” Genome Biol. 2013 Oct 7;14(10):R108. PMID: 24098934
  63. Pellagatti A, Benner A, Mills K, Cazzola M, Giagounidis AAN, Perry J, Malcovati L, Giovanni M, Porta D, Jädersten M,  Verma A, McDonald E, Killick S, Hellstrom-Lindberg E, Bullinger L, Wainscoat JS, Boultwood J, “Identification of gene expression based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes.” JCO 2013 Oct 1;31(28):3557-64. PMID: 24002510
  64. Lam AP, Gundabolu K, Sridharan A, Jain R, Msaouel P, Chrysofakis G, Yu Y, Friedman E, Price E, Schrier S, Verma AK,  “Multiplicative interaction between mean corpuscular volume and red cell distribution width in predicting mortality of elderly patients with and without anemia.”  Am J Hematol. 2013 Nov;88(11):E245-9. PMID: 23828763
  65. Yang X, Song JH, Cheng Y, Wu W, Bhagat T, Yu Y, Abraham JM, Ibrahim S, Ravich Roland W, Khashab M, Singh VK, Shin EJ, Yang X, Verma A, Meltzer SJ, Mori Y, “Long Noncoding RNA HNF1A-AS1 Regulates Proliferation and Migration in Esophageal Adenocarcinoma Cells.” Gut 2013 Sep 2. PMID: 24000294 
  66. Bajpai M, Kessel R, Bhagat T, Nischal S, Yu Y, Verma A*, Das K, *Co-Corresponding,  “High resolution integrative analysis reveals widespread genetic and epigenetic changes after chronic in-vitro acid and bile exposure in Barrett's epithelium cells.” Genes Chromosome Cancer 2013 Oct 3. PMID: 24123713
  67. Mehrotra S, Sharma B, Joshi S, Kroczynska B, Majchrzak B, Stein BL, McMahon B, Altman JK, Licht JD, Baker DP, Eklund EA, Wickrema A, Verma A, Fish EN, Platanias LC, “Essential role for the Mnk-pathway in the inhibitory effects of Type I interferons on myeloproliferative neoplasm (MPN) precursors.”  JBC, 2013 Aug 16;288(33):23814-22 PMID: 23814052
  68. Bhattacharyya, Si; Yu, Y; Suzuki, M; Campbell, N; Mazdo, J; Vasantkumar, A; Bhagat, T; Nischal, S; Christopeit, M; Parekh, S; Steidl, U; Godley, L; Maitra, A; Greally, J; Verma, A;  “Genome wide hydroxymethylation tested using the HELP-GT assay shows redistribution in cancer.” Nucleic Acid Res 2013  Sep;41(16):e157 PMID: 23861445
  69. Will B, Vogler TO, Bartholdy B, Garrett-Bakelman F, Mayer J, Barreyro L, Pandolfi A, Todorova TI, Okoye-Okafor UC, Stanley RF, Bhagat TD, Verma A, Figueroa ME, Melnick A, Roth M, Steidl U, “Satb1 regulates the self-renewal of hematopoietic stem cells by promoting quiescence and repressing differentiation commitment.” Nat Immunol. 2013 May;14(5):437-45. PMID: 23563689
  70. Bhagat T, Zhou L, Sokol L, Caceres G, Gundabolu K, Gordon S, Mantzaris I, Gligich O, Yu Y, Bhattacharyya S, Jing X, Polineni R, Tamari R, Bhatia K, Pellagatti A , Boultwood J, Kambhampati S, Steidl U, Stein C, Ju W, Liu G, Kenny P, List A, Bitzer M, Verma A,  “miR-21 mediates hematopoietic suppression in MDS by activating TGF-bsignaling.” Blood 2013, Apr 11;121(15):2875-81. PMID: 23390194
  71. Yu Y, Mo Y, Liu H, Bhattacharyya S, Ebenezer D, Sundaravel S, Caces B, Ulaszek J, Artz A, Nischal S, Bhagat T, Bathon K, Maqbool S, Suzuki M, Steidl U, Godley L, Skoultchi A, Greally J, Wickrema A, Verma A, “High resolution methylome analysis reveals widespread hypomethylation during human erythroid differentiation.” JBC 2013 Mar 29;288(13):8805-14. PMID: 23306203
  72. Heuck C, Mehta J, Bhagat T, Gundabolu K, Yu Y, Khan S, Chrysofakis G, Schinke C, Tariman J, Vickrey E, Pulliam N, Nischal S, Zhou L, Bhattacharya S, Meagher R, Hu C, Maqbool S, Suzuki M, Parekh S, Reu F, Steidl U, Greally J, Verma A*, Singhal S,* Co-Corresponding, “Myeloma is characterized by stage specific alterations in DNA methylation that occur early during myelomagenesis.”  Journal of Immunology 2013 Mar 15;190(6):2966-75. PMID: 23408834
  73. Wu W, Bhagat T, Yang X, Song J, Cheng Y, Agarwal R, Abraham J, Ibrahim S, Bartenstein M, Hussain Z, Suzuki M, Yu Y, Eng C, Greally J, Verma A*, Meltzer SJ*, Co-Corresponding, “Hypomethylation of Noncoding DNA Regions and Overexpression of the Long Noncoding RNA, AFAP1-AS1, in Barrett’s Esophagus and Esophageal Adenocarcinoma.” Gastroenterology 2013 May;144(5):956-966. PMID: 23333711
  74. Nischal S, Bhattacharyya S, Christopeit N, Yu Y, Zhou L, Bhagat T, Sohal S, Will B, Mo Y, Suzuki M, Pardanani A, McDevitt M, Maciejewski J, Melnick A, Greally J, Steidl U, Moliterno A, Verma A,  “Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms.” Cancer Res, 2012 Dec 27. PMID: 23066032
  75. Will B, Zhou L, Vogler TO, Ben-Neriah S, Schinke C,Tamari R, Yu Y, Bhagat T,  Bhattacharya S, Barreyro L, Heuck C, Mo Y, Parekh S, McMahon C, Pellagatti A, Boultwood J, Montagna C, Silverman L, Maciejewski J, Greally JM, Ye BH, List AF, Steidl C, Steidl U, Verma A,  “Stem and progenitor cells in myelodysplastic syndromes show aberrant stage specific expansion and harbor genetic and epigenetic alterations.” Blood 2012; 120(10):2076-86. PMID: 22753872
  76. Sokol L, Cripe L, Kantarjian H, Sekeres MA, Parmar S, Greenberg P, Goldberg SL, Bhushan V, Shammo J, Hohl R, Verma A, Garcia-Manero G, Li YP, Lowe A, Zhu J, List AF, “Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome.” Leukemia. 2012 Sep 11. PMID: 23032694
  77. Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley RF, Ben-Neriah S, Montagna C, Parekh S, Pellagatti A, Boultwood J, Paietta E, Ketterling RP, Cripe L, Fernandez, Greenberg PL, Tallman MS, Steidl C, Mitsiades CS, Verma A, Steidl U, “Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.” Blood. 2012 Aug 9;120(6):1290-8. PMID: 22723552
  78. Jerez A, Sugimoto Y, Makishima H, Verma A, Jankowska AM, Przychodzen B, Visconte V, Tiu RV, O'Keefe CL, Mohamedali AM, Kulasekararaj AG, Pellagatti A, McGraw K, Muramatsu H, Moliterno AR, Sekeres MA, McDevitt MA, Kojima S, List A, Boultwood J, Mufti GJ, Maciejewski JP,  “Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis.”   Blood. 2012 Jun 21;119(25):6109-17. PMID: 22553315
  79. Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS, Verma A, Steidl U., “Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation.” Blood. 2012 May 24. PMID: 22627766
  80. Barta SK, Zou Y, Schindler J, Shenoy N, Bhagat TD, Steidl U, Verma A., “Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia.” Leuk Lymphoma.2012 Apr 18.  PMID: 22448921
  81. Stein BL, Williams DM, O'Keefe C, Rogers O, Ingersoll RG, Spivak JL, Verma A, Maciejewski JP, McDevitt MA, Moliterno AR, “Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.”   Haematologica. 2011 Oct;96(10):1462-9. Epub 2011 Jun 28. PMID: 21712540
  82. Sharma B, Altman JK, Goussetis DJ, Verma AK, Platanias LC, “Protein kinase R as mediator of the effects of interferon (IFN) gamma and tumor necrosis factor (TNF) alpha on normal and dysplastic hematopoiesis.” J Biol Chem. 2011 Aug 5;286(31):27506-14. Epub 2011 Jun 9. PMID:1659535
  83. Zhou L, Opalinska J, Sohal D, Yu Y, Mo Y, Bhagat T, Abdel-Wahab O, Fazzari M, Figueroa M, Alencar C, Zhang J, Kanbhampati S, Parmar S, Nischal S, Heuck C, Suzuki M, Friedman E, Pellagatti A, Boultwood J, Steidl U, Sauthararajah Y, Yajnik V, Gore SD, Platanias LC, Levine R, Melnick A, Wickrema A, Greally JM, Verma A,  “Aberrant epigenetic and genetic marks are seen in myelodysplastic leucocytes and reveal DOCK4 as a candidate pathogenic gene on chr7q.” J Biol Chem. 2011 Apr 30. PMID: 21532034 
  84. Alvarez H, Opalinska J, Zhou L, Sohal D, Fazzari M, Yu Y, Montagna C, Montgomery E, Canto M, Dunbar K, Wang J, Roa J, Mo Y, Bhagat T, Ramesh K, Cannizzaro L, Mollenhauer J, Thompson R, Suzuki M, Meltzer S, Melnick A, Greally JM, Maitra A, Verma A, “Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis.” PLOS Genetics 2011 Mar;7(3) PMID: 21483804
  85. L Zhou, C McMahon, T Bhagat, C Alencar, Y Yu, M Fazzari, D Sohal, C Heuck, K Gundabolu, C Ng, Y Mo, W Shen, A Wickrema, G Kong, E Friedman, L Sokol,  G Mantzaris, A Pellagatti , J Boultwood, LC Platanias, U Steidl, L Yan, JM Yingling, MM Lahn, A List, M Bitzer and A Verma, “Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase.” Cancer Research 2011 Feb 1;71(3):955-63.PMID: 21189329
  86. Joshi S, Sharma B, Kaur S, Majchrzak B, Ueda T, Fukunaga R, Verma AK, Fish EN, Platanias LC, “Essential role for Mnk kinases in type II interferon (IFNgamma) signaling and its suppressive effects on normal hematopoiesis.”  
    J Biol Chem. 2011 Feb 25;286(8):6017-26.PMID: 21149447
  87. Kroczynska B, Joshi S, Eklund EA, Verma A, Kotenko SV, Fish EN, Platanias LC, “Regulatory effects of ribosomal S6 kinase 1 (RSK1) in IFNλ signaling.” J Biol Chem. 2011 Jan 14;286(2):1147-56. Epub 2010 Nov 12.
  88. Schinke C, Goel S, Bhagat TD, Zhou L, Mo Y, Gallagher R, Kabalka GW, Platanias LC, Verma A*, Das B, “Design and synthesis of novel derivatives of all-trans retinoic acid demonstrate the combined importance of acid moiety and conjugated double bonds in its binding to PML-RAR-alpha oncogene in acute promyelocytic leukemia.” 
    Leuk Lymphoma. 2010 Jun;51(6):1108-14. PMID: 20536349
  89. Huh J, Tiu RV, Gondek LP, O'Keefe CL, Jasek M, Makishima H, Jankowska AM, Jiang Y, Verma A, Theil KS, McDevitt MA, Maciejewski JP, “Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis.” Genes Chromosomes Cancer. 2010 Apr;49(4):390-9. PMID: 20095039
  90. Pellagatti A, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta MG, Jädersten M, Verma A, Norbury C Hellström-Lindberg E, Wainscoat JS, Boultwood J, “Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.” Leukemia. 2010 Apr;24(4):756-64. PMID: 20220779
  91. Einstein F, Thompson RF, Bhagat TD, Fazzari MJ, Verma A, Barzilai N, Greally JM, “Cytosine methylation dysregulation in neonates following intrauterine growth restriction.” PLoS One. 2010 Jan 26;5(1):e8887 PMID: 20126273
  92. Oda M., Glass J.L., Thompson R.F., Mo Y., Olivier E., Figueroa M.E., Selzer R.R., Richmond T.A., Zhang X., Dannenberg L., Green R., Melnick A., Hatchwell E., Bouhassira E., Verma A., Suzuki M., Greally J.M., “High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers.” Nucleic Acids Res. 2009 Jul;37(12):3829-39.   PMID: 19386619
  93. Sohal D, Yeatts A, Ye K, Pellagatti A, Zhou L, Pahanish P, Mo Y, Bhagat T, Mariadason J, Boultwood J, Melnick A, Greally JM, Verma A, “Meta-analysis of microarray studies reveals a novel hematopoietic progenitor cell signature and demonstrates feasibility of inter-platform data integration.” PLOS One 2008 Aug 13;3(8):e2965    PMID: 18698424
  94. Zhou L, Nguyen AN, Sohal D, Ma JY, Pahanish P, Gundabolu K, Hayman J, Chubak A,   Mo Y, Bhagat T, Das B, Haghnazari E, Navas T, Parmar S, Kambhampati S, Pellagati A,  Braunchweig I, Zhang YE, Wickrema A, Boultwood J, Platanias LC, Higgins LS, List A, Bitzer M, Verma A, “Inhibition of Transforming Growth Factor beta receptor I kinase can stimulate hematopoiesis in Myelodysplasia.”       Blood 2008 Oct 15;112(8):3434-43  PMID: 18474728
  95. Navas T, Zhou L, Estes M, Haghnazari E, Nguyen A, Mo Y, Pahanish P, Mohindru M, Cao T, Higgins L, Platanias LC, List A, Verma A, “Inhibition of p38a MAPK disrupts the pathological loop of proinflammatory factor production in the Myelodysplastic Syndrome bone marrow microenvironment.”  Leukemia and Lymphoma 2008 Oct;49(10):1963-75
  96. Zhou L, Opalinska J, Verma A, “p38 MAP kinase regulates stem cell apoptosis in human hematopoietic failure.” Cell Cycle 2007, 1;6(5):534
  97. Navas T, Mohindru M, Estes M, Ma JY, Sokol L, Pahanish P, Parmar S, Haghnazari E, Zhou L, Collins RC, Kerr I, Nguyen A, Xu Y, Platanias LC, List AA, Higgins LS, Verma A, “Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors.” Blood 2006, 15;108(13):4170-7
  98. Verma A, and List A, “Cytokine Targets in Myelodysplastic syndromes.” Current Hematology Reports 2005 Nov;4(6):429-35
  99. Deonarain R, Verma A, Porter AC, Gewert DR, Platanias LC, Fish EN, “Critical roles for IFN-beta in lymphoid development, myelopoiesis, and tumor development: links to tumor necrosis factor alpha.” Proc Natl Acad Sci USA. 2003 Nov 11;100(23):13453-8
  100. Verma A, Devine S, Morrow M, Chen YH, Mihalov M, Peace D, Stock W, Pursell K, Wickrema A, Yassine M, Jessop E, Van Besien K, “Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir.”  Bone Marrow Transplant. 2003 May;31(9):813-6.
  101. Verma A., Mohindru M., Deb D., Sassano A., Kambhampati S., Minucci S., Ravandi F., Kovakanalu D, Platanias L., “Activation of the Rac1 and p38 MAP kinase pathway in response to Arsenic trioxide.”  Journal of Biological Chemistry 22;277(47):44988-95
  102. Verma A, Sassano A, Deb D, Wickrema, A., VanBesien K., and Platanias L., “Blockade of p38 MAP kinase reverses cytokine mediated inhibition in aplastic anemia.” Journal of Immunology 2002, 168 (12) (Cutting edge section)
  103. Verma A, Deb D.K., Sassano A., Uddine S., Wickrema A., Varga and Platanias LC, “Activation of the p38 mitogen activated protein kinase mediates suppressive effects of Type I interferons and transforming growth factor-b on normal hematopoiesis.” Journal of Biological Chemistry 2002, 277(10):7726-35
  104. Devine S, Hoffman R, Verma A, Shah R, Bradlow B, Stock W and Van Besien K, “Allogeneic blood cell transplantation following reduced intensity conditioning is effective therapy for older patients with myelofibrosis.” Blood  2002, 99(6):2255-8

Review articles

  1. Li W, Morrone K, Kambhampati S, Will B, Steidl U, Verma A, “Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.” Leukemia, 2015 (In Press)
  2. Shenoy N, Vallumsetla N, Zou Y, Galeas JN, Shrivastava M, Hu C, Susztak K, Verma A., "Role of DNA methylation in renal cell carcinoma." J Hematol Oncol. 2015 Jul 22;8(1):88. PMID: 26198328
  3. Verma A, Steidl U., “A synthetic lethal approach targeting mutant isocitrate dehydrogenase in acute myeloid leukemia.” 
    Nat Med. 2015;21:113-4.  PMID: 25654599
  4. Gañán-Gómez I, Wei Y, Starczynowski DT, Colla S, Yang H, Cabrero-Calvo M, Bohannan ZS, Verma A, Steidl U, Garcia-Manero G, "Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes." Leukemia. 2015 Mar 12. PMID: 25761935
  5. Shenoy N, Vallumsetla N,  Rachmilewitz E, Verma A, Ginzburg Y., "Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome." Blood, 2014 Aug 7;124(6):873-81. PMID: 24923296
  6. Das BC, Thapa P, Karki R, Das S, Mahapatra S, Liu TC, Torregroza I, Wallace DP, Kambhampati S, Van Veldhuizen P, Verma A, Ray SK,    Evans T.,  "Retinoic acid signaling pathways in development and diseases."
    Bioorg Med Chem. 2014 Jan 15;22(2):673-83. PMID: 24393720
  7. Elias HK, Schinke C, Bhattacharyya S, Will B*, Verma A*,  Steidl U* *CoCorresponding,    “Stem cell origin of myelodysplastic syndromes.” Oncogene 2013 Dec 16. PMID: 24336326
  8. Pathak S, Roth M, Verma A*, Steidl U*.  *CoCorresponding,    “Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders.”
    Expert Opin Drug Metab Toxicol. 2013 Dec;9(12):1667-75. PMID: 24215532
  9. Feld J, Barta SK, Schinke C, Braunschweig I, Zhou Y, Verma AK,  “Linked-in: design and efficacy of antibody drug conjugates in oncology.” Oncotarget 2013 Mar;4(3):397-412. PMID: 23651630
  10. Khan H, Vale C, Bhagat T, Verma A.,   “Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes.”
    Semin Hematol. 2013 Jan;50(1):16-37. PMID: 23507481
  11. Elias H, Verma A,  “Activation of hypoxia signaling is marker of poor prognosis in myelodysplasia.”
    Leuk Lymphoma. 2012 Dec;53(12):2337-8. PMID: 22897726
  12. Shenoy N, Kessel R, Bhagat TD, Bhattacharyya S, Yu Y, McMahon C, Verma A.,  “Alterations in the ribosomal machinery in cancer and hematologic disorders.” J Hematol Oncol. 2012 Jun 18;5:32. PMID: 22709827
  13. Agarwal A, Polineni R, Hussein Z, Vigoda I, Bhagat TD, Bhattacharyya S, Maitra A, Verma A.,  “Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma.” Int J Clin Exp Pathol. 2012;5(5):382-96. PMID: 22808291
  14. Sharma A,  Heuck C, Fazzari M, Mehta J, Singhal S, Greally JM, Verma A,  “DNA methylation alterations seen in myeloma as a model of epigenetic changes in cancer.” WIREs Systems Biology and Medicine 2010 Nov-Dec;2(6):654-69. PMID: 20890963
  15. Schinke C, Mo Y, Yu Y, Amiri K, Sosman J, Greally JM, Verma A,  “Aberrant DNA methylation in malignant melanoma.” Melanoma Research 2010, Aug; 20(4):253-65 PMID: 20418788
  16. Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, Verma A., “Mechanism of action of lenalidomide in hematological malignancies.”
    J Hematol Oncol. 2009 Aug 12;2:36
  17. Opalinska J, Zhou L, Verma A., “A new PML-RARs fusion transcript hints at the important role of PML dysregulation in the pathogenesis of APL.” Leukemia Research (Commentary) 2007, 48(3):443
  18. Isufi I, Seetharam M, Sohal D, Zhou L, Opalinska J, Pahanish P, Verma A., “Transforming Growth Factor-beta Signaling in Normal and Malignant Hematopoiesis.” Journal of Interferon and Cytokine Research 2007, 27(7):543
  19. Mohindru M, Verma A,  “Engineered antibodies act as targeted therapies in cancer treatment.” Indian Journal of Pediatrics, 2005 Nov;72(11):943-7
  20. Sassano A, Verma A, Platanias LC, "Mitogen-activated protein kinase pathways in interferon signaling." Methods Molecular Medicine, 2005;116:135-50.
  21. Mohindru M, Verma A, "Kinase inhibitors translate lab discoveries into exciting new cures for cancers." Indian Journal of Pediatrics, 2004 Aug;71(8):713-8.
  22. Verma A, Kambhampati S, Parmar S, Platanias LC,  “Jak family of kinases in cancer.” Cancer Metastasis Rev. 2003 Dec;22(4):423-34.(rev)
  23. Verma A, and Platanias LC, “Signaling via the interferon-a receptor in chronic myelogenous leukemia cells.” Leukemia and Lymphoma  2002, 44:703-709
  24. Verma A, and Stock W, “Management of adult lymphoblastic leukemia: moving toward a risk-adapted approach.” Current Opinion in Oncology, 2001, 13:14-20
  25. Verma A, and Gupta YK,  “The search for a super oral rehydration solution (0RS).” Drugs: News and Views, 1995, 3(2):129-132. 

More Information About Dr. Amit Verma


Material in this section is provided by individual faculty members who are solely responsible for its accuracy and content.

Albert Einstein College of Medicine
Jack and Pearl Resnick Campus
1300 Morris Park Avenue
Chanin Building, Room 302B
Bronx, NY 10461

Tel: 718.430.8761
Fax: 718.430.8702

Research Information

In the News

COVID-19 Vaccines ARE Effective in Cancer Patients

Balazs Halmos, M.D., and Amit Verma, M.B.B.S., comment on their study that finds patients with cancer developed antibodies to COVID-19 after vaccination. Dr. Halmos is director of the Multidisciplinary Thoracic Oncology Program at Montefiore and professor of medicine at Einstein; Dr. Verma is associate director of translational science at the Albert Einstein Cancer Center and director of the division of hemato-oncology at Montefiore.

NBC News reports on research by Drs. David Prezant and Amit Verma that finds firefighters exposed to the 9/11 World Trade Center disaster site face an increased risk for a blood cancer precursor.

More media coverage